Quick Facts: Uses of Buserelin-long

Condition
Management of hormone-dependent prostate cancer
Treatment for the symptoms of endometriosis
Pre-treatment for controlled ovarian hyperstimulation (IVF)
Management of uterine fibroids

---

Buserelin-long is a prescription medication utilized in several therapeutic domains related to hormone-sensitive conditions. Its primary role involves supporting the management of certain disorders where the reduction of specific reproductive hormone levels is medically beneficial.

In oncology, this medication is approved for the palliative treatment of advanced, hormone-dependent prostate cancer, where it helps reduce testosterone levels. For patients with gynecological disorders, Buserelin is used to manage symptoms associated with endometriosis and to support the treatment of uterine fibroids (leiomyomas).

Additionally, Buserelin plays a role in reproductive medicine. It is administered to regulate the ovarian cycle as a part of assisted reproductive technology (ART) protocols, such as in vitro fertilization (IVF), which permits precise timing for subsequent steps in the procedure. The use of this drug is considered a strategy for controlling the timing of the reproductive cycle in fertility treatments.

Regulatory References

1. Health Canada therapeutic overview

Eligibility Map: Who Can and Cannot Use Buserelin-long

Official regulatory documents define strict criteria for the use of Buserelin-long, a Gonadotropin-Releasing Hormone (GnRH) agonist, classifying patient populations into three main categories: allowed, restricted, and contraindicated.

Category	Eligibility Rule (Official Statement)
Populations Allowed	Adult Males (for prostate cancer) and Adult Females (for gynecological indications and IVF).
Contraindicated	Patients with known hypersensitivity to Buserelin or any GnRH analogue, pregnancy (confirmed or suspected), or breastfeeding (lactation).
	Males with confirmed non-hormone dependent carcinoma or who have undergone orchiectomy.
	Females with undiagnosed abnormal vaginal bleeding.

Age-Related Eligibility: Use is established for the adult population. Safety and efficacy for the primary oncological and gynecological indications are not established in pediatric patients (under 18 years).

Condition-Specific Restrictions: The medicine requires special caution and monitoring in patients with pre-existing conditions. These include uncontrolled hypertension, a history of depression, diabetes mellitus, and patients with severe hepatic or renal impairment.

Official Eligibility Statements:

• Buserelin-long is contraindicated during pregnancy, and non-hormonal contraception must be used.
• Caution is mandatory for patients at risk of spinal cord compression or ureteric obstruction during the initial phase of prostate cancer treatment.

This structure reflects how regulatory labeling defines who can safely receive the medicine, based on their physiological state, age, and existing comorbidities.

Interactions with other medicines and products

The interaction profile of Buserelin-long (Buserelin acetate depot) focuses on officially documented pharmacodynamic risks and cautions related to co-administered substances. All interaction information is based strictly on regulatory labeling from authorized government health bodies.

---

Documented Pharmacodynamic and Efficacy Interactions

Interaction Type	Interacting Agent Category	Official Regulatory Statement
QTc Interval Risk	Medicinal products known to prolong the QTc interval (e.g., specific antiarrhythmics)	Co-administration requires careful evaluation due to the potential for additive QTc prolongation.
Efficacy Attenuation	Antidiabetic agents (e.g., oral hypoglycemics, insulins)	The therapeutic effect of these agents may be attenuated (reduced) during Buserelin treatment.
Electrolyte Imbalance	Corticosteroids	Increases the risk of additive hypokalaemia, which can heighten the risk for cardiac rhythm disturbances.

---

Population and Excipient Caution

Constraint Type	Interacting Substance/Condition	Regulatory Note
Excipient Clearance	Severe liver or kidney impairment	Increased risk of accumulation and toxicity from the excipient Benzyl alcohol due to impaired clearance.

---

Official labeling does not document any specific pharmacokinetic interactions involving CYP enzymes or drug transporters that affect Buserelin exposure. Furthermore, the regulatory documents for the depot formulation do not specify timing-based separation rules or explicit interactions with food, alcohol, or herbal products.

The mechanism of action for Бусерелин-лонг (Buserelin) is defined by its systemic manipulation of the central hormonal control system, resulting in a controlled suppression of sex hormone production.

Pituitary Receptor Down-Regulation

This mechanism addresses the core molecular interaction: Buserelin, a potent agonist, continuously stimulates the GnRH receptors in the pituitary gland. This non-stop exposure causes the receptors to become unresponsive through a process called down-regulation, establishing a functional blockade of the central hormone release site.

HPG Axis Silencing and Biphasic Action

The resulting pituitary blockade immediately silences the entire Hypothalamic-Pituitary-Gonadal (HPG) Axis) signaling cascade. While this process is ultimately suppressive, it involves a necessary biphasic action, starting with a transient surge (the flare-up) of LH and FSH, which must occur before the continuous pituitary suppression takes hold.

Arrest of Gonadal Steroid Production

The systemic consequence of the pituitary blockade is the profound and continuous suppression of LH and FSH secretion. This removes the critical signal required by the testes and ovaries to synthesize sex hormones, leading to a core physiological change: a rapid and continuous reduction in circulating Testosterone and Estradiol levels, achieving concentrations typical of sustained gonadal suppression. The long-acting formulation is designed to provide the continuous, non-pulsatile exposure required to maintain this receptor down-regulation.

How to Use Бусерелин-лонг: Official Administration Guidelines

Бусерелин-лонг (Buserelin) is a prolonged-release formulation that must be administered strictly according to prescribing information. The instructions below summarize the requirements for its proper use.

Administration and Dosage Schedule

Category	Official Instruction
Route of Administration	Deep Intramuscular (IM) injection
Standard Dose	3.75 mg of the lyophilisate reconstituted as a suspension
Frequency	Once every 4 weeks (28 days)
Course Duration (Gynecological)	Limited to a maximum of 4 to 6 months (e.g., for endometriosis)

Preparation and Procedural Requirements

Preparation: The medicine is provided as a lyophilisate (powder) that requires reconstitution with the provided solvent immediately before injection to form a suspension. This preparation must be carried out only by trained medical personnel. The suspension should be mixed using gentle circular movements (not shaken vigorously) until it is homogenous.

Procedural Rules: The entire, fully prepared suspension must be administered as a slow, deep intramuscular injection. For all repeat injections, the healthcare professional should alternate the injection site (e.g., left and right gluteal muscles). When used for gynecological conditions, the first dose must be administered within the first five days of the menstrual cycle.

Missed Dose: If the scheduled 4-week injection is missed, it should be administered as soon as feasible. The subsequent injection schedule must then be adjusted to maintain the required 4-week interval from the date of the catch-up injection.

Research evidence / Overview of studies for Buserelin-long

Evidence for Use in Hormone-Dependent Prostate Cancer

Research for this condition has been conducted to explore patterns observed over time, focusing on hormonal suppression. This body of evidence primarily includes Randomized Controlled Trials (RCTs) and large-scale meta-analyses. These studies monitored oncologic outcomes such as overall survival and the time until the disease showed signs of progression. Studies monitored hormonal levels in patient cohorts, researching whether chemical castration thresholds were measured.

Research so far indicates that while the evidence quality is generally High, it often relies on comparative trials, meaning Buserelin-long was studied for its patterns in comparison to other treatments. Few data are available from studies not comparing it to a known treatment. Results apply only to the populations studied.

Evidence for Use in Gynecological Conditions

Endometriosis Symptom Research

Controlled clinical trials and long-term observational follow-up studies were performed in women with endometriosis. The research examined patient-reported outcomes describing perceived physical discomfort such as pelvic pain. Studies monitored how symptoms evolved during a defined treatment period. Research highlights changes measured during the study period, but symptom recurrence after the cessation of therapy is an observation point that remains variable across the reported studies. Evidence for long-term outcomes is not fully established beyond short-term treatment.

Uterine Fibroid Volume Studies

Systematic reviews and prospective clinical trials was studied for the patterns of Buserelin-long in women with symptomatic uterine fibroids. The research explored short-term changes, measuring fibroid and uterine volume. Research observing long-term outcomes described a pattern where volume changes were often not sustained after the medication was discontinued. Data for certain groups remain insufficient.

Evidence in Assisted Reproductive Technology (ART) Protocols

Randomized Controlled Trials (RCTs) and prospective comparative studies was evaluated in women undergoing ART, such as In Vitro Fertilization (IVF). This research examined the medication’s role in Controlled Ovarian Hyperstimulation (COH) protocols, monitoring clinical reproductive outcomes like live birth rates and clinical pregnancy rates. Comparative research describes patterns related to pituitary down-regulation as measured for cycle control. Comparative studies exploring differences between the long-acting injection and daily administration noted some variability in the measurement of required units of co-administered hormone drugs and the duration of stimulation.

Key Studies & References American Society for Reproductive Medicine (ASRM) Guidance on controlled ovarian hyperstimulation protocols

Common questions about Бусерелин-лонг (FAQ)

Q: What is the primary medical use of Бусерелин-лонг?

According to official product information, Бусерелин-лонг is used to treat hormone-dependent conditions. These indications include prostate cancer in men and specific gynecological conditions in women, such as endometriosis and uterine fibroids. It is also used as part of protocols for assisted reproductive technology (ART).

Q: Is Бусерелин-лонг the same medicine as other generic buserelin injections?

While it shares the same active ingredient (Buserelin), the 'long' form is a depot preparation designed for a sustained-release effect. This means it is injected and then slowly released over an extended period (e.g., for monthly use), which differs from daily injectable or nasal spray formulations.

Q: What is the expected timeline for the drug to start taking effect?

Official information describes a temporary surge in sex hormones, sometimes called a 'flare-up,' that marks the start of the drug's action. This initial phase typically occurs during the first week of treatment before the intended continuous hormonal suppression is achieved.

Q: Are the side effects permanent or do they stop once treatment is over?

The side effects of Бусерелин-лонг are primarily linked to the controlled suppression of sex hormones. According to regulatory documents, these effects and associated symptoms are generally expected to be reversible once treatment is officially discontinued.

Q: Is weight gain listed as a common or uncommon side effect?

Changes in weight, including both gain and loss, are listed as a possible adverse reaction in the official product information. This effect is typically classified within the uncommon frequency category, meaning it may affect up to 1 in every 100 people who use the medicine.

Q: Does taking blood pressure medication cause issues with this drug?

Official labeling indicates that caution is necessary for patients with pre-existing high blood pressure. Additionally, the drug may increase the risk of heart rhythm problems when taken alongside certain medicines, including specific classes of antiarrhythmics, which can affect the heart's rhythm.

Q: Will fertility return to normal after stopping the treatment?

The hormonal suppression caused by this medicine may lead to a temporary state of sterility or chemical menopause while in use. Regulatory information suggests that sexual function and desire are generally expected to return after the treatment course is stopped.

Q: Is it considered a chemotherapy drug?

Бусерелин-лонг is classified as a Gonadotropin-Releasing Hormone (GnRH) agonist, which is a form of endocrine therapy (or hormone therapy). This classification distinguishes it from conventional cytotoxic chemotherapy, as it works by managing hormone production rather than directly killing fast-growing cells.

Q: What should I do if the injection site becomes painful or swollen?

Local reactions at the injection site, such as pain, swelling, or reddening, are listed as a Very Common and expected adverse effect in official documents. Official guidance describes contacting a healthcare professional if any local reaction is severe, persistent, or causes significant discomfort.

Q: Is it safe to drive or operate machinery after receiving the injection?

Official safety information states that certain reported side effects, such as dizziness, can potentially affect concentration and reaction time. Due to this potential risk, caution is advised when operating vehicles, tools, or heavy machinery.

Q: Does the effect of the drug differ between male and female patients?

The core mechanism is the same in all patients: it suppresses the signals from the pituitary gland to the gonads. However, the physiological result differs: in men, it leads to a profound reduction in Testosterone levels, and in women, it leads to a profound reduction in Estradiol and Progesterone levels.

Q: Does this medicine impact cholesterol levels?

Studies on this class of hormonal therapy indicate that long-term use may contribute to an increase in cardiovascular risk factors. This includes the potential for changes to the body's lipid or cholesterol profile, a condition known as dyslipidemia.

Q: How is this type of treatment monitored by doctors?

Monitoring of the treatment response involves regular clinical assessment by a doctor and required laboratory tests. These tests typically include measuring the levels of sex hormones and monitoring disease-specific markers, such as PSA in men being treated for prostate cancer.

Q: What does the scientific community generally say about the long-term prognosis after this treatment?

Long-term prognosis and outcomes are dependent on the condition being treated. While the therapy is documented to support survival outcomes for prostate cancer, studies for gynecological conditions often report that symptoms may recur after the treatment course has ended.

Storage and Disposal Requirements for Buserelin

Storage and disposal must strictly adhere to regulatory requirements to maintain the stability of this peptide medicine and ensure safety.

Storage Conditions

Storage Requirement	Official Condition
Temperature	Store at or below 25 C (room temperature); Do not freeze
Protection	Keep in the original package and protect from light and moisture
Security	Must be kept out of the sight and reach of children and stored locked up (P405)

Disposal

Disposal Requirement	Official Instruction
Waste Type	Dispose of as hazardous or special waste (P501)
Environmental	Avoid release to the environment (P273); Do not throw into household waste or wastewater

All expired or unused product must be taken to a designated special waste collection point in compliance with local, regional, and national regulations.